[12] Patent
[11] Patent No.:GC0007508  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/125427
Date of the Decision to Grant the Patent:04/Apr/2018

[21] Application No.:GC 2010-16039

[22] Filing Date:9/6/2010

[30] Priority:

[33] State [32] Priority date [31] Priority No.

[72] Inventors:1- Kazutomo Kinoshita،2- Kohsuke Asoh،3- Noriyuki Furuichi،4- Toshiya Ito،5- Hatsuo Kawada،6- Nobuya Ishii،7- Hiroshi Sakamoto،8- Woo sang Hong،9- Min jeong Park،10- Yoshiyuki Ono،11- Yasuharu Kato،12- Kenji Morikami،13- Takashi Emura،14- Nobuhiro Oikawa

[73] Owner: Chugai Seiyaku Kabushiki Kaisha, 5-1, Ukima 5-chome, Kita-ku, Tokyo 115-8543, Japan

[74] Agent: Saud M. A. Shawwaf Law Office




Int. Cl.: A61K 31/343, 31/381; C07D 209/88 (2006.01)

[56] Cited Documents:

-WO 2008051547 A1 (CEPHALON INC.) 02 May 2008
-JP 08092090 A (TANABE SEIYAKU CO.) 09 April 1996
-WO 2009073620 A2 (NEWLINK GENETICS) 11 June 2009
Examiner: PH. Nada M. AlBehaiji

[57] Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).
No. of claims: 7


Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.